1. Home
  2. KAVL vs NEUP Comparison

KAVL vs NEUP Comparison

Compare KAVL & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kaival Brands Innovations Group Inc.

KAVL

Kaival Brands Innovations Group Inc.

HOLD

Current Price

$0.47

Market Cap

9.6M

Sector

Health Care

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.37

Market Cap

10.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
KAVL
NEUP
Founded
1998
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.6M
10.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
KAVL
NEUP
Price
$0.47
$4.37
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$28.00
AVG Volume (30 Days)
62.5K
172.8K
Earning Date
09-16-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,127,037.00
$15,649,448.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.40
$2.90
52 Week High
$1.55
$21.40

Technical Indicators

Market Signals
Indicator
KAVL
NEUP
Relative Strength Index (RSI) 41.41 36.97
Support Level $0.46 $4.13
Resistance Level $0.50 $4.60
Average True Range (ATR) 0.04 0.30
MACD 0.00 0.28
Stochastic Oscillator 15.60 24.08

Price Performance

Historical Comparison
KAVL
NEUP

About KAVL Kaival Brands Innovations Group Inc.

Kaival Brands Innovations Group Inc is focused on growing and incubating creative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: